Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia

Ishikawa, Kazuhiro; Matsuo, Takahiro; Tsuda, Yasumasa; Rahman, Mahbubur; Uehara, Yuki; Mori, Nobuyoshi

doi:10.3390/antibiotics11020254

Cited by 3 publications

(1 citation statement)

References 16 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another interesting cohort is the patients on hemodialysis (HD). Patients on HD who received >9 mg/kg of daptomycin were significantly associated with DEP [ 13 ]. In patients on HD, mortality with vancomycin treatment was significantly lower compared to patients on daptomycin despite similar clinical and microbiological effectiveness.…”

Section: Discussionmentioning

confidence: 99%

Daptomycin-Induced Pulmonary Toxicity: A Case Series

Patel¹,

Natarajan²,

Ramakrishna³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Daptomycin-Induced Pulmonary Toxicity: A Case Series

Patel¹,

Natarajan²,

Ramakrishna³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series

Gidari,

Pallotto,

Francisci

2024

Infection

View full text Add to dashboard Cite

Purpose Daptomycin-induced eosinophilic pneumonia (DIEP) is a rare yet severe adverse event that requires rapid recognition and management. Diagnosing a definite case is challenging and involves meeting the American Thoracic Society (ATS) criteria, although alternative criteria have been suggested. This study aims to conduct a systematic review of literature and includes a case series. Methods Six cases of DIEP identified at Perugia Hospital, Perugia, Italy have been described. A systematic review was carried out adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines. Results a total of 74 cases of DIEP were analysed. Using ATS clinical criteria, 15 were classified as definite (20.3%), 54 as probable (73.0%), and 5 as possible (6.8%). Phillips criteria and the Lyon Algorithm identified 43/74 (58.2%) and 64/67 (95.5%) cases as definite, respectively. Bronchoalveolar lavage (BAL) was performed in 43 cases, revealing an average eosinophil count of 28.6% (SD 24.4). Radiological findings highlighted recurring features like bilateral opacities (68.1%), ground-glass opacities (41.7%), patchy infiltrates (30.6%), and peripheral predominance (19.4%). Upon suspicion, daptomycin was discontinued; 20 cases required no additional treatment, 38 received corticosteroids, and 12 received both corticosteroids and antibiotics. Recovery rates were high across all treatment types (≥ 73.7%). Most reports described rapid improvement post-withdrawal (within 96 h). Conclusions DIEP is a rare, fast-progressing condition where early diagnosis and prompt treatment are vital. Diagnosis relies on clinical, laboratory, and radiological evaluations. Stopping daptomycin is essential, with corticosteroids often necessary. Further research is needed to enhance diagnostic accuracy for this disease.

show abstract

Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System

Okada

Niimura

Saisyo

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Eosinophilic pneumonia (EP) is a rare adverse event caused by several types of drugs, such as antibiotics; however, its characteristics remain poorly described. This study aimed to analyze the disproportionality between the occurrence of EP and anti-methicillin-resistant Staphylococcus aureus (MRSA) agents and to characterize anti-MRSA agent-induced EP events using the Food and Drug Administration Adverse Event Reporting System (FAERS). Method Disproportionality linking EP and anti-MRSA agents was analyzed using Bayesian confidence propagation neural networks of information components and reporting odds ratio methodologies. The FAERS dataset for the fourth quarter of 2012 to the fourth quarter of 2022 was used. We also analyzed the characteristics of the case of EP induced by anti-MRSA agents. Results A total of 14,805,795 reports were obtained from FAERS. Disproportionality analysis revealed that the EP signal was detected only in cases with the administration of daptomycin (DAP). This disproportionality signal was consistently detected in the sensitivity analysis. Compared to other reports of DAP-related adverse events, the reports of DAP-related EP were characterized by male sex (odds ratio (OR): 1.94, 95% confidence interval (CI): 1.12–3.37), older age (>70 years; OR: 2.70, 95% CI: 1.68–4.33), and longer duration of treatment (over 21 days; OR: 5.08, 95% CI: 3.21–8.05). Conclusion This study revealed that among the anti-MRSA agents, disproportionality in the occurrence of EP was observed only with DAP. Our results suggest that sex, age, and treatment duration may affect the occurrence of DAP-induced EP. Clinicians should exercise caution regarding EP during DAP administration.

show abstract

Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia

Cited by 3 publications

References 16 publications

Daptomycin-Induced Pulmonary Toxicity: A Case Series

Daptomycin-Induced Pulmonary Toxicity: A Case Series

Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series

Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System

Contact Info

Product

Resources

About